A calcium transport mechanism for atrial fibrillation in Tbx5-mutant mice

Wenli Dai††, Brigitte Laforest††, Leonid Tyan†, Kaitlyn M Shen‡, Rangarajan D Nadadur‡, Francisco J Alvarado§, Stefan R Mazurek¶, Sonja Lazarević*, Margaret Gadek†, Yitang Wang†, Ye Li†, Hector H Valdivia§, Le Shen§, Michael T Broman¶, Ivan P Moskowitz*, Christopher R Weber†*

††Department of Pathology, University of Chicago, Chicago, United States; ‡Departments of Pediatrics, Pathology, and Human Genetics, University of Chicago, Chicago, United States; ¶Department of Medicine, Division of Cardiovascular Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, United States; §Department of Medicine, University of Chicago, Chicago, United States; ¶¶Section of Neurosurgery, Department of Surgery, University of Chicago, Chicago, United States

Abstract Risk for Atrial Fibrillation (AF), the most common human arrhythmia, has a major genetic component. The T-box transcription factor TBX5 influences human AF risk, and adult-specific Tbx5-mutant mice demonstrate spontaneous AF. We report that TBX5 is critical for cellular Ca\(^{2+}\) homeostasis, providing a molecular mechanism underlying the genetic implication of TBX5 in AF. We show that cardiomyocyte action potential (AP) abnormalities in Tbx5-deficient atrial cardiomyocytes are caused by a decreased sarcoplasmic reticulum (SR) Ca\(^{2+}\) ATPase (SERCA2)-mediated SR calcium uptake which was balanced by enhanced trans-sarcolemmal calcium fluxes (calcium current and sodium/calcium exchanger), providing mechanisms for triggered activity. The AP defects, cardiomyocyte ectopy, and AF caused by TBX5 deficiency were rescued by phospholamban removal, which normalized SERCA function. These results directly link transcriptional control of SERCA2 activity, depressed SR Ca\(^{2+}\) sequestration, enhanced trans-sarcolemmal calcium fluxes, and AF, establishing a mechanism underlying the genetic basis for a Ca\(^{2+}\)-dependent pathway for AF risk.

DOI: https://doi.org/10.7554/eLife.41814.001

Introduction Atrial fibrillation (AF) is the most common arrhythmia in humans, characterized by irregularly irregular atrial electrical activity, resulting in asynchronous atrial contraction. AF is a global problem, affecting more than 33 million people and approximately 25% of Americans over the age of forty (Nishida and Nattel, 2014; Weng et al., 2018). AF is associated with significant morbidity and mortality due to thromboembolic events, heart failure, and sudden cardiac death. AF also significantly complicates overall health care management, with AF patients costing five times more to treat than patients without AF (Andrade et al., 2014). The total annual cost to treat AF patients in the US is on the order of 26 billion dollars (Nishida and Nattel, 2014). AF is a highly significant and growing public health concern.

A genetic basis for AF risk has been described in the last decade. Large community-based cohort studies indicate that heritability provides between 40% and 62% of AF risk (Nishida and Nattel, 2014; Christophersen et al., 2009). An emerging paradigm describes AF as a multifactorial disease with genetic predisposition that will determine the propensity of secondary clinical insults to cause AF. This model highlights the importance of understanding the molecular mechanisms underlying...
the genetic predisposition to AF. Genome-wide association studies (GWAS) studies have identified common risk variants and familial mutations at the T-box transcription factor 5 (TBX5) locus that result in increased risk for AF (McDermott et al., 2008; Sinner et al., 2014). Adult-specific Tbx5 knockout mice demonstrate primary spontaneous and sustained AF, providing evidence supporting the genetic implication at this locus. GWAS have also implicated multiple genes involved in cardiomyocyte calcium handling, including Atp2a2, encoding the sarcolemmal calcium ATPase SERCA2, and Sln and Pln, encoding direct binding SERCA2 inhibitors sarcolipin and phospholamban, respectively. We have previously demonstrated that these cardiomyocyte calcium control genes are direct TBX5 targets (Nadadur et al., 2016). These observations suggested that tight transcriptional control of SERCA2 activity may be central to atrial rhythm robustness and that variation in SERCA2 expression and activity may contribute to AF risk.

The cellular mechanisms causing the irregular electrical activity in AF are believed to include an abnormal myocardial substrate and formation of an ectopic trigger. Abnormal substrate refers to altered electrical conduction between cardiomyocytes. Ectopic trigger refers to cardiomyocyte ectopy, or initiation of electrical activity at regions outside of the sinoatrial node. Both of these cellular phenomena are observed in Tbx5 adult-specific mutant mice and have been associated with abnormal cellular calcium handling (Dobrev, 2010; Voigt et al., 2012; Voigt et al., 2014; Vest et al., 2005; Shanmugam et al., 2011; Neet et al., 2010; Macquaide et al., 2015; Liang et al., 2008; Lenaerts et al., 2009; Hove-Madsen et al., 2004; Greiser et al., 2011; El-Armouche et al., 2006; Brundel et al., 1999). We described the TBX5-dependent gene regulatory network essential for atrial rhythm control and identified downstream ion channels and transporters potentially important to rhythm control (Nadadur et al., 2016; Yang et al., 2017). Triggered activity in the form of early and delayed afterdepolarizations (EADs and DADs) observed in Tbx5-deficient atrial cardiomyocytes could be rescued by heavy buffering of cytoplasmic calcium (Nadadur et al., 2016).
2016). Tbx5-dependent calcium handling has thereby emerged as a potential mediator of the myocardial physiologic abnormalities resulting in AF.

We sought to define the Tbx5-dependent cellular mechanisms responsible for abnormal calcium-dependent electrical activity. We found that Tbx5-dependent AF is associated with abnormal sarcoplasmic reticulum (SR) calcium uptake due to depressed SERCA2 expression, depressed SERCA function, and increased phospholamban expression. Decreased SR calcium uptake is compensated by increased Ca$$^{2+}$$ extrusion from cardiomyocytes via sodium-calcium exchanger (NCX) current ($$I_{\text{NCX}}$$), which provides a mechanism for Tbx5-dependent action potential (AP) prolongation and the propensity for triggered cellular ectopy. In the setting of enhanced NCX mediated Ca$$^{2+}$$ efflux and depressed SR uptake, compensatory increases in L-type calcium current ($$I_{\text{Ca,L}}$$) balance calcium extrusion to maintain steady state calcium homeostasis. Together these calcium handling alterations contribute to AP prolongation and triggered activity.

We further demonstrated that calcium handling abnormalities, AP alterations, and triggered activity are all normalized by knockout of phospholamban, which prevents Tbx5-dependent AF. These results establish a direct link between depressed SR Ca$$^{2+}$$ sequestration, enhanced NCX activity, and AF. This model suggests that targeting calcium handling pathways may be a treatment approach for a subpopulation of AF patients.

Results

Cytoplasmic calcium is responsible for AP prolongation in Tbx5-mutant atrial cardiomyocytes

We previously reported that Tbx5-deficient atrial cardiomyocytes demonstrated AP prolongation and myocardial ectopy. We hypothesized that these defects were caused by cellular calcium handling abnormalities. We therefore surveyed the expression of known calcium handling genes in the adult-specific Tbx5 knockout model. We assessed gene expression in Tbx5$$^{5/5};$$R26$$^{\text{CreERT2}}$$ and control R26$$^{\text{CreERT2}}$$ mice at 10 weeks of age following tamoxifen (TM) treatment at 8 weeks of age. Consistent with previous observations, the adult Tbx5$$^{5/5};$$R26$$^{\text{CreERT2}}$$ but not control mice developed spontaneous AF, showing an irregularly irregular heartbeat, by telemetric electrocardiogram (ECG) recordings (Figure 1A, B). As previously shown, APs and [Ca]$$^{2+}$$ transients were prolonged in Tbx5$$^{5/5};$$ R26$$^{\text{CreERT2}}$$ (Figure 1C) (Nadadur et al., 2016). We assessed expression of genes important to cellular calcium handling in the left atrium by quantitative PCR (Figure 1D). mRNA transcripts for RyR2 ($$Ryr2$$) and SERCA2 ($$Atp2a2$$), two of the main determinants of sarcoplasmic reticulum (SR) calcium flux, were decreased by 61% and 71% respectively in Tbx5$$^{5/5};$$R26$$^{\text{CreERT2}}$$ mice compared to R26$$^{\text{CreERT2}}$$ controls (p=0.026 and p=0.001 for $$Ryr2$$ and $$Atp2a2$$ respectively) consistent with previous studies (Nadadur et al., 2016). In addition, phospholamban ($$Pln$$) mRNA expression was increased by 69% in Tbx5$$^{5/5};$$R26$$^{\text{CreERT2}}$$ compared to R26$$^{\text{CreERT2}}$$ (p=0.023), which would be expected to further depress SERCA2 activity. There was no significant difference in mRNA expression of the alpha 1C subunit of the L-type calcium channel ($$Cacna1c$$), the cardiac sodium calcium exchanger ($$Ncx1$$), or any of the calmodulins 1–3 ($$Calm1$$, $$Calm2$$, $$Calm3$$) (Figure 1C). These data are consistent with the hypothesis that the myocardial electrophysiology deficits in the Tbx5-deficient AF model may be due to abnormal calcium handling.

We examined the relationship between myocardial electrophysiology deficits and calcium flux in Tbx5-mutant atria. In steady state, with each cardiomyocyte contraction cycle, calcium entering the cardiomyocyte (L-type calcium channel, $$I_{\text{Ca,L}}$$) is extruded from the cell (predominantly via inward $$I_{\text{NCX}}$$). Similarly, calcium leaving the SR via RyR2 release or SR leak pathways is taken back up into the SR via SERCA2. We examined the effect of altered Tbx5-dependent gene expression on these aspects of cardiomyocyte calcium flux. Given the observed changes in $$Ryr2$$ and $$Atp2a2$$ mRNA abundance, we hypothesized that AP prolongation in Tbx5 deficient cardiomyocytes was due to calcium handling defects downstream of initial Ca$$^{2+}$$ entry through $$I_{\text{Ca,L}}$$. To test this, we recorded APs in the presence and absence of the L-type Ca$$^{2+}$$ channel blocker nifedipine. This approach blocks Ca$$^{2+}$$ entry into the cell and indirectly removes the effect of Ca$$^{2+}$$ entry on downstream Ca$$^{2+}$$ handling pathways, including SR Ca$$^{2+}$$ release/reuptake as well as the electrogenic effect of calcium transport out of the cell via inward $$I_{\text{NCX}}$$. 30 μM nifedipine completely inhibited L-type calcium current, preventing Ca$$^{2+}$$ entry or release of SR calcium in control R26$$^{\text{CreERT2}}$$ and Tbx5$$^{5/5};$$R26$$^{\text{CreERT2}}$$ (Figure 2—
Figure 1. Atrial fibrillation in Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup> mice is associated with altered expression of genes important to cellular calcium handling. (A) Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup> mice developed spontaneous AF as assessed by surface ECG compared to R26<sup>CreERT2</sup>. Traces are representative of 15 animals per genotype. (B) Poincaré plot shows irregularly irregular rhythm in Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup>, consistent with AF, compared to normal sinus rhythm in R26<sup>CreERT2</sup> mice. Poincaré plots are each from one animal, and representative of 15 animals per genotype. (C) Simultaneous AP and [Ca]<sub>i</sub> recordings show
prolonged AP duration and slowed \([\text{Ca}^2+]\) transient decay in Tbx5\(^{0/6};\) R26\(^{\text{CreERT2}}\) atrial cardiomyocytes compared to R26\(^{\text{CreERT2}}\). Recordings are representative of simultaneous \([\text{Ca}^2+]\) and \(E_m\) recordings (myocytes/mice; dual \(E_m\) and \([\text{Ca}^2+]\), from 5/5 R26\(^{\text{CreERT2}}\) and 17/5 Tbx5\(^{0/6};\) R26\(^{\text{CreERT2}}\), \(E_m\) only from 23/9 R26\(^{\text{CreERT2}}\) and 20/9 Tbx5\(^{0/6};\) R26\(^{\text{CreERT2}}\), \([\text{Ca}^2+]\) only from 27/6 R26\(^{\text{CreERT2}}\) and 28/6 Tbx5\(^{0/6};\) R26\(^{\text{CreERT2}}\)). (D) Quantitative PCR was performed on RNA isolated from left atrial tissue of 3–5 animals per genotype. mRNA expression of a panel of calcium handling genes potentially important for rhythm regulation was determined.

Figure supplement 1. qPCR data for Figure 1D. DOI: https://doi.org/10.7554/eLife.41814.005

The following source data and figure supplement are available for figure 1:

**Source data 1.** qPCR data for Figure 1D. DOI: https://doi.org/10.7554/eLife.41814.004

**Figure supplement 1.** PCR primers. DOI: https://doi.org/10.7554/eLife.41814.004

**figure supplement 1.** In control R26\(^{\text{CreERT2}}\) atrial cardiomyocytes, the effect of nifedipine on AP duration (APD) was small, with 19 ± 4% shortening of APD at 90% repolarization (APD90) (\(p=0.008\)) (Figure 2A). However, in Tbx5\(^{0/6};\) R26\(^{\text{CreERT2}}\) atrial cardiomyocytes, nifedipine had a profound effect: APD at 50% repolarization (APD50) was shortened by 16 ± 6% and APD90 by 61 ± 6% (\(p=0.02\) and 0.007 respectively) (Figure 2B, C). Western blot with densitometry analysis for \(Ca_{1.2}\) showed no significant difference in protein expression (Figure 2D), in line with the qPCR data (Figure 1D), consistent with no change in TRX5-driven direct transcriptional regulation of L-type calcium channels. However, peak \(I_{\text{CaL}}\) current was increased 92 ± 34% (\(p=0.027\)) in Tbx5\(^{0/6};\) R26\(^{\text{CreERT2}}\) atrial cardiomyocytes compared to control R26\(^{\text{CreERT2}}\) (Figure 2E and F). The inactivation kinetics at peak \(I_{\text{CaL}}\) were accelerated Tbx5\(^{0/6};\) R26\(^{\text{CreERT2}}\) compared to control R26\(^{\text{CreERT2}}\) (\(\tau= 26.7 ± 3.4\) ms vs. \(\tau= 40.0 ± 3.0\) ms; \(p=0.05\)). Steady-state \(I_{\text{CaL}}\) inactivation was unchanged (Figure 2—figure supplement 2). These data suggest that increased \(I_{\text{CaL}}\) may contribute to TBX5-loss associated AP prolongation and EADs. However, nifedipine also blocks SR Ca\(^{2+}\) release as well as downstream Ca\(^{2+}\) extrusion pathways, which also affect AP duration. Further, since late AP repolarization is dramatically prolonged (negative to –30 mV where \(I_{\text{CaL}}\) is largely inactive) we hypothesized that Tbx5-deficiency disrupts Ca\(^{2+}\) handling pathways downstream of \(I_{\text{CaL}}\).

**Removal of Tbx5 results in decreased Ca\(^{2+}\) sparks and RyR2 expression, but no overall reduction in RyR2 open probability**

Because RyR2 is a critically important sarcolemmal calcium extrusion channel and Ryr2 mRNA was downregulated in Tbx5-mutant atria, we investigated the Tbx5 dependent regulation of RyR2 protein expression and function. RyR2 protein expression was significantly decreased in left atria of Tbx5\(^{0/6};\) R26\(^{\text{CreERT2}}\) mice compared to R26\(^{\text{CreERT2}}\) mice by western blot (Figure 3A), consistent with the observed downregulation of Ryr2 mRNA (Figure 1B). We hypothesized that decreased RyR2 contributed to abnormal Ca\(^{2+}\) release from the SR and tested this by measuring local spontaneous RyR2-mediated Ca\(^{2+}\) release events (Ca\(^{2+}\) sparks) using confocal linescans (Figure 3B). The frequency of Ca\(^{2+}\) sparks in Tbx5\(^{0/6};\) R26\(^{\text{CreERT2}}\) atrial cardiomyocytes was decreased in comparison with R26\(^{\text{CreERT2}}\) atrial cardiomyocytes at different pacing frequencies from 0 to 2 Hz (Figure 3C). A decrease in calcium sparks can be due to either decreased RyR2 open probability or a reduced SR calcium load. To differentiate these possibilities, we first examined RyR2 function in the setting of reduced RyR2 expression by performing a \(^{3}H\)-ryanodine binding assay. \(^{3}H\)-ryanodine binding to RyR2 correlates with RyR2 open probability (Dobrev, 2010). Despite reduced ryanodine receptor expression, overall ryanodine binding was unchanged over the majority of the physiological range of calcium values, with no shift in calcium sensitivity (Figure 3D). This observation suggests that the alterations in spark frequency were not due to changes in total RyR2 open probability. Instead, it may be caused by diminished SR Ca\(^{2+}\) uptake, a SERCA-dependent property.

**Adult-specific Tbx5 deficiency reduces SERCA activity and SR load while increasing sodium-calcium exchanger activity**

We next focused on the balance of diastolic calcium efflux pathways as potential mediators of Ca\(^{2+}\) mishandling by measuring SR Ca\(^{2+}\) content and protein expression and function of SERCA2 and...
Figure 2. Calcium current blockade dramatically shortened the AP in Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup> atrial cardiomyocytes, consistent with the [Ca]<sub>i</sub> dependence of AP prolongation following TBX5 loss. (A) Representative recording of an AP from R26<sup>CreERT2</sup> atrial cardiomyocytes before and after 30 µM nifedipine treatment. (B) Representative recording of a Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup> atrial cardiomyocytes before and after nifedipine treatment. (C) Paired AP properties before and after treatment with 30 µm nifedipine (myocytes/mice; n = 8/3 Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup> and n = 6/4 R26<sup>CreERT2</sup>). In R26<sup>CreERT2</sup> cardiomyocytes, the effect of nifedipine on APD90 was small, but significant 19 ± 4%. A much larger nifedipine effect was observed in Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup> cardiomyocytes. APD50 decreased by 16 ± 6% and APD90 decreased by 61 ± 6% in the presence of nifedipine. (D) Western blot of atrial tissue in five animals for each genotype showed protein expression for the alpha 1C subunit of the L-type calcium channel (Ca<sub>v</sub>1.2) was unchanged. (normalized to GAPDH) (E,F) Representative I<sub>CaL</sub> recordings show Peak L-type calcium current was increased in Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup> cardiomyocytes compared to R26<sup>CreERT2</sup> (G) Average IV relationship of L-type calcium current (myocytes/mice; n = 22/7 R26<sup>CreERT2</sup> and 20/5 Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup>). (**p<0.001, *, p<0.01, *, p<0.05). DOI: https://doi.org/10.7554/eLife.41814.006

The following source data and figure supplements are available for figure 2:

Source data 1. AP and I<sub>CaL</sub> parameters for Figure 2C,G.

Figure 2 continued on next page
NCX1. We observed that SERCA2 protein expression was decreased while NCX1 protein expression was increased in Tbx5^{fl/fl};R26^{CreERT2} in comparison with R26^{CreERT2} atria (Figure 4A,B). To define steady state SR Ca^{2+} content, we loaded cardiomyocytes with Fluo-4 AM and paced with a train of field stimuli to achieve a steady state Ca^{2+} content, peak Ca^{2+} content, and rate of Ca^{2+} removal were measured (Figure 4C,D). The [Ca^{2+}]_i transient peaks were unchanged, but [Ca^{2+}]_i transient decay rates, corresponding to SR Ca^{2+} uptake and cellular Ca^{2+} extrusion, were slowed in Tbx5^{fl/fl};R26^{CreERT2}. 

Figure 3. Spark frequency is reduced in Tbx5^{fl/fl};R26^{CreERT2} atrial cardiomyocytes. (A) Western blot from atrial tissue from 10 animals per genotype was used to measure RyR2 expression. RyR2 was significantly decreased in Tbx5^{fl/fl};R26^{CreERT2} atria compared to R26^{CreERT2} atria (normalized to GAPDH). (B) Fluo-4 loaded cardiomyocytes demonstrated reduced spark frequency in Tbx5^{fl/fl};R26^{CreERT2} compared to R26^{CreERT2} atrial cardiomyocytes (representative recordings). (C) Spark frequency was reduced at rest and after steady state pacing at different frequencies (myocytes/mice; n = 12/4 Tbx5^{fl/fl};R26^{CreERT2} and n = 12/3 R26^{CreERT2}). (D) Ryanodine binding assay (without normalization) demonstrated no significant difference over the physiologic range of [Ca] in Tbx5^{fl/fl};R26^{CreERT2} compared to R26^{CreERT2} (Weng et al., 2018). Each measure corresponds to an assay performed on pooled atria from 8 to 10 mice with three independent measures per condition (*p<0.05, **p<0.01, ***p<0.001).

The following source data is available for figure 3:

Source data 1. Western blot for Figure 3A.
DOI: https://doi.org/10.7554/eLife.41814.013

Source data 2. Spark analysis for Figure 3C.
DOI: https://doi.org/10.7554/eLife.41814.014

Source data 3. Ryanodine binding assay for Figure 3D.
DOI: https://doi.org/10.7554/eLife.41814.015
Figure 4. SERCA function is decreased while NCX function is increased in Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup> atrial cardiomyocytes. (A) Expression of SERCA2 was significantly decreased (normalized to GAPDH) while (B) expression of NCX1 was significantly increased in Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup> atria compared to R26<sup>CreERT2</sup> atria as measured by western blot in 10 animals per genotype. (normalized to GAPDH) (C) Application of Na<sup>+</sup>-free caffeine solution after pacing to steady state at 1 Hz provided a measurement of SR load. In the absence of extracellular Na<sup>+</sup>, [Ca<sup>2+</sup>]i plateaued at high levels due to negligible role of non-NCX mediated extrusion in R26<sup>CreERT2</sup> and Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup> atrial cardiomyocytes. Removal of caffeine in the absence of external Na<sup>+</sup> provided a measure of SERCA mediated SR calcium uptake (representative traces). (D) Restoration of external Na<sup>+</sup>, in the presence of sustained extracellular caffeine provided a measure of NCX mediated calcium efflux (representative traces). (E) The peak of steady state twitch [Ca<sup>2+</sup>]i transients was similar but (F) tau of [Ca<sup>2+</sup>]i decay, determined from twitch [Ca<sup>2+</sup>]i transients, was increased in Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup> compared to R26<sup>CreERT2</sup> cardiomyocytes (myocytes/mice; n = 27/6 R26<sup>CreERT2</sup>, n = 28/6 Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup>). (G) SR load, determined from peak caffeine transients was decreased in Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup> compared to R26<sup>CreERT2</sup> cardiomyocytes (myocytes/mice; n = 34/6 R26<sup>CreERT2</sup>, n = 32/6 Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup>). (H) SERCA activity, determined from the maximal rate of calcium decay was diminished in Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup> compared to R26<sup>CreERT2</sup> cardiomyocytes (myocytes/mice; n = 27/6 R26<sup>CreERT2</sup>, n = 28/6 Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup>). (I) NCX activity

Figure 4 continued on next page.
n = 29/3 R26\textsuperscript{CreERT2}, n = 32/3 Tbx5\textsuperscript{fl/fl};R26\textsuperscript{CreERT2}). (I) NCX activity (decay slope), was increased at all levels of calcium in Tbx5\textsuperscript{fl/fl};R26\textsuperscript{CreERT2} compared to Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2}. (*p<0.05, **p<0.01, ***p<0.001).

The following source data and figure supplements are available for figure 4:

**Source data 1.** Western blot for NCX activity for cardiomyocytes (myocytes/mice; n = 29). DOI: https://doi.org/10.7554/eLife.41814.021

**Source data 2.** Ca\textsuperscript{2+} handling parameters for Source data 3. NCX activity for Figure 4I. DOI: https://doi.org/10.7554/eLife.41814.020

**Source data 3.** NCX activity for Figure 4I. DOI: https://doi.org/10.7554/eLife.41814.021

**Figure supplement 1.** [Ca\textsuperscript{2+}], transients recorded using 40 ms voltage clamp pulses demonstrate 23 ± 4% (p=0.02) reduction in peak calcium in Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2} compared to R26\textsuperscript{CreERT2} atrial cardiomyocytes. DOI: https://doi.org/10.7554/eLife.41814.017

**Figure supplement 1—source data 1.** Ca\textsuperscript{2+} transients for Figure 4—figure supplement 1. DOI: https://doi.org/10.7554/eLife.41814.018

**Figure 4 continued**

R26\textsuperscript{CreERT2} compared to R26\textsuperscript{CreERT2} atrial cardiomyocytes (Figure 4E,F) (Nadadur et al., 2016), consistent with defective Ca\textsuperscript{2+} removal from the cytosol. We also measured [Ca\textsuperscript{2+}], transients in voltage clamp mode using 40 ms square wave voltage clamp pulses from ~80 to 0 mV (Figure 4—figure supplement 1). Similar to the field stimulation experiments, [Ca\textsuperscript{2+}], transient decay rates were slowed, but [Ca\textsuperscript{2+}], transient peaks were decreased by 23 ± 4% (p=0.02) in Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2} cardiomyocytes compared to R26\textsuperscript{CreERT2}, which suggests that AP prolongation is essential to maintaining peak twitch [Ca\textsuperscript{2+}]. The latter experiment is also consistent with depressed SR loads in Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2} compared to R26\textsuperscript{CreERT2} atrial myocytes.

We hypothesized that decreased SERCA2 expression caused decreased SR load. We examined SERCA activity by synchronizing the opening of RyR2 channels while preventing Ca\textsuperscript{2+} extrusion through NCX using caffeine containing, sodium-free, Tyrode solution. This provides a measurement of the maximum release of Ca\textsuperscript{2+} into the cytosol from the SR, a measure of the SR Ca\textsuperscript{2+} load (Figure 4C,D). SR [Ca\textsuperscript{2+}] was reduced by 24 ± 8% (p=0.0005) in Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2} compared with R26\textsuperscript{CreERT2} atrial cardiomyocytes (Figure 4E,F). SERCA activity was assessed from [Ca\textsuperscript{2+}], decay rate after SR release in the absence of external sodium (NCX inactive). Peak SERCA activity was reduced by 31 ± 9% (p=0.006) in Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2} compared with R26\textsuperscript{CreERT2} atrial cardiomyocytes (Figure 4C,H). NCX activity was assessed as the rate of change in [Ca\textsuperscript{2+}], decay in Na\textsuperscript{+} containing caffeine solution, preventing net SR uptake. Since NCX activity depends on [Ca\textsuperscript{2+}], we plotted NCX as a function of the [Ca\textsuperscript{2+}] signal. NCX activity was ~60% higher in Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2} in comparison with R26\textsuperscript{CreERT2} atrial cardiomyocytes (Figure 4D,I). Thus, removal of Tbx5 causes decreased SR Ca\textsuperscript{2+} load and decreased SERCA function, but increased NCX mediated Ca\textsuperscript{2+} extrusion. Increased inward NCX activity promotes cardiomyocyte depolarization, providing a mechanism for prolonged APs and increased ectopy in Tbx5-mutant atrial cardiomyocytes.

**Genetic augmentation of SERCA activity and normalization of SR load eliminates susceptibility to AF**

We hypothesized that Tbx5 deficiency reduces SERCA activity by decreasing SERCA2 protein expression (Figure 4A) and increasing expression of phospholamban (Pln), a negative regulator of SERCA2 (Figure 1D). If these were the primary causes of decreased SERCA function in Tbx5-mutant atria, reduced PLN or PLN phosphorylation (releasing inhibition of SERCA2) would be expected to normalize SERCA function. Western blot analysis showed that PLN expression was significantly increased in Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2} compared with R26\textsuperscript{CreERT2} atria (Figure 5A). In addition, PLN phosphorylation was also increased at serine 16 in Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2} compared to R26\textsuperscript{CreERT2}. These data suggest PLN phosphorylation may be a compensatory mechanism in response to decreased SERCA expression and activity, but is insufficient to normalize SERCA function (Figure 4). Thus, we hypothesized that reduction of Pln gene expression would be more effective in restoring SERCA function.
Figure 5. Phospholamban knockout normalized SERCA function in Tbx5\(^{+/+}, R26^{CreERT2}\). (A) PLN expression was increased in Tbx5\(^{+/+}, R26^{CreERT2}\) compared to R26\(^{CreERT2}\) as measured by western blot with five animals per genotype. PLN expression was normalized to GAPDH. The proportion of PLN S16, but not T17 phosphorylation was also increased (normalized to PLN). (B) Representative SR load and SERCA measurements in R26\(^{CreERT2}\), Tbx5\(^{+/+}, R26^{CreERT2}\), Pln\(^{-/-}\), R26\(^{CreERT2}\) and Tbx5\(^{+/+}, Pln^{+/+}, R26^{CreERT2}\) atrial cardiomyocytes were collected as described in Figure 4. (C-D) SR load and SERCA function were significantly higher in Tbx5\(^{+/+}, Pln^{+/+}, R26^{CreERT2}\) and Tbx5\(^{+/+}, R26^{CreERT2}\) compared to Tbx5\(^{+/+}, R26^{CreERT2}\) cardiomyocytes and comparable to R26\(^{CreERT2}\) cardiomyocytes. (E) [Ca\(^{2+}\)] transient peaks were unchanged in Tbx5\(^{+/+}, R26^{CreERT2}\), Tbx5\(^{+/+}, Pln^{-/-}, R26^{CreERT2}\), but increased in Pln\(^{-/-}\), R26\(^{CreERT2}\) cardiomyocytes. (F) [Ca\(^{2+}\)] transient decay rate in Tbx5\(^{+/+}, Pln^{-/-}\), R26\(^{CreERT2}\) and Tbx5\(^{+/+}, Pln^{-/-}, R26^{CreERT2}\) cardiomyocytes were normalized to that of R26\(^{CreERT2}\) cardiomyocytes (myocytes/mice; n = 34/3 R26\(^{CreERT2}\), n = 36/3 Tbx5\(^{+/+}, R26^{CreERT2}\), n = 30/3 Pln\(^{-/-}, R26^{CreERT2}\), n = 21/3 Tbx5\(^{+/+}, Pln^{-/-}, R26^{CreERT2}\), n = 27/3 Tbx5\(^{+/+}, Pln^{-/-}\) atrial cardiomyocytes). (*)p<0.05, **p<0.01, ***p<0.001.

DOI: https://doi.org/10.7554/eLife.41814.022

The following source data is available for figure 5:
Source data 1. Western blot for Figure 5A.
DOI: https://doi.org/10.7554/eLife.41814.023
Source data 2. Ca\(^{2+}\) Handling parameters for Figure 5C–F.
DOI: https://doi.org/10.7554/eLife.41814.024

We assessed if Pln deficiency can affect SERCA function in a dose dependent manner by crossing the Tbx5\(^{+/+}, R26^{CreERT2}\) with germline Pln knockout mice (Pln\(^{-/-}\), R26\(^{CreERT2}\)) (Luo et al., 1994). We compared SR load and SERCA function in adult-specific Tbx5; Pln double mutant mice versus Tbx5 mutant mice. We measured SR load and SERCA function using caffeine-induced SR release in atrial
cardiomyocytes from R26\textsuperscript{CreERT2}; Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2}; Pln\textsuperscript{-/-}; R26\textsuperscript{CreERT2}, Tbx5\textsuperscript{fl/fl}, Pln\textsuperscript{-/-}; R26\textsuperscript{CreERT2} mice, and Tbx5\textsuperscript{fl/fl}, Pln\textsuperscript{-/-}; R26\textsuperscript{CreERT2} mice. Control Pln deficient mice (Pln\textsuperscript{-/-}; R26\textsuperscript{CreERT2}) had increased steady state SR load and SERCA activity relative to R26\textsuperscript{CreERT2} (Figure 5C,D). The decreased SR load and SERCA function observed in Tbx5 mutant mice (Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2}) was converted to elevated SR load and SERCA function after the removal of Pln (Tbx5\textsuperscript{fl/fl}, Pln\textsuperscript{-/-}; R26\textsuperscript{CreERT2}) (Figure 5C,D). Pln loss alone increased peak twitch calcium. However, in the setting of combined Tbx5;Pln deficiency, peak twitch calcium and tau twitch were normalized to R26\textsuperscript{CreERT2} values (Figure 5E,F).

We next tested the possibility that decreased SERCA function was the mechanism of TBX5-deficiency-driven AP prolongation and triggered activity and that decreased Pln may rescue these defects. As we previously showed, Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2} atrial cardiomyocytes exhibited significantly prolonged APs and frequent EADs and DADs compared to R26\textsuperscript{CreERT2} atrial cardiomyocytes (Figure 6A,B) (Nadadur et al., 2016). APs of Pln\textsuperscript{-/-}; R26\textsuperscript{CreERT2} atrial cardiomyocytes were similar to R26\textsuperscript{CreERT2} controls (Figure 6C). The prolonged AP duration observed Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2} was rescued in both Tbx5\textsuperscript{fl/fl}, Pln\textsuperscript{-/-}; R26\textsuperscript{CreERT2} and Tbx5\textsuperscript{fl/fl}, Pln\textsuperscript{-/-}; R26\textsuperscript{CreERT2} atrial cardiomyocytes (43 ± 10% and 38 ± 5% shorter than Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2} respectively; p = 0.01, 0.0007) (Figure 6D,E). Along with normalization of AP duration, we observed significantly fewer EADs and DADs in Tbx5\textsuperscript{fl/fl}, Pln\textsuperscript{-/-}; R26\textsuperscript{CreERT2} cardiomyocytes (Figure 6F). The data demonstrate the importance of TBX5-driven SERCA activity on cellular electrophysiology and triggered activity in atrial cardiomyocytes and decreased Pln rescues both SERCA function and cardiocyte electrophysiological abnormalities in Tbx5-mutant mice.

The data above show reducing Pln gene dosage rescues calcium handling defects, AP prolongation and triggered activity observed in Tbx5-mutant atrial cardiomyocytes. We hypothesized that normalizing these cardiomyocyte cellular defects would reduce AF susceptibility in Tbx5 knockout mice (Figure 7). We performed intracardiac burst pacing. All Tbx5\textsuperscript{fl/fl}, R26\textsuperscript{CreERT2} mice (6/6) paced into AF, compared to none of the R26\textsuperscript{CreERT2} (0/5) or Pln\textsuperscript{-/-}; R26\textsuperscript{CreERT2} littermate controls (0/7). Consistent with our hypothesis, AF susceptibility was significantly decreased in Tbx5; Pln compound knockouts: only 1/11 of Tbx5\textsuperscript{fl/fl}; Pln\textsuperscript{-/-}; R26\textsuperscript{CreERT2} paced into AF (Figure 7F). Thus, Tbx5-deficiency induced AF is due to calcium handling abnormalities, specifically decreased SR load and SERCA activity, and that modulation of the SERCA2 inhibitor, Pln, normalized SERCA activity and AF susceptibility caused by Tbx5 loss.

Discussion

AF initiation has been linked to calcium handling abnormalities in computational and in vivo disease models (Grandi et al., 2011; Heijman et al., 2014). Ectopic or triggered activity in the form of EADs and DADs are often due to calcium handling abnormalities that increase NCX activity and promote AF initiation (Heijman et al., 2014). However, the mechanism underlying genetic predispositions for AF remain poorly understood. Genetic variants and mutations at the Tbx5 locus are associated with increased risk for human AF and Tbx5-mutant mice show both spontaneous and burst pacing-induced AF (Nadadur et al., 2016). We report a calcium transport mechanism for Tbx5-dependent ectopic activity. We show that TBX5 is a critical regulator of SERCA-mediated SR calcium handling and that Tbx5-deficient mice have increased NCX-mediated Ca\textsuperscript{2+} extrusion, balanced by increased I\textsubscript{Cal} mediated Ca\textsuperscript{2+} influx. These calcium handling abnormalities provide a mechanism explaining the frequent triggered activity observed after Tbx5 knockout. We show that decreasing phospholamban dosage can normalize TBX5-loss associated cellular calcium handling abnormalities, shorten AP duration, prevent triggered activity, and diminish AF susceptibility.

Decreased SERCA activity and SR load in TBX5-loss associated atrial fibrillation

We and others have hypothesized that ectopic triggers of AF can be due to abnormal atrial calcium handling (Greiser et al., 2011; Bers and Grandi, 2011). Here we define this relationship in a model of spontaneous AF. We analyzed the major calcium transport pathways in atrial myocytes and demonstrated that the critical calcium handling deficit associated with Tbx5-loss is depressed SERCA-mediated SR calcium uptake. We report significant reduction of SERCA2 protein expression and function, consistent with human paroxysmal or chronic AF (Voigt et al., 2012; Voigt et al., 2014; El-Armouche et al., 2006; Brundel et al., 1999).
Figure 6. PLN knockout normalized AP duration and prevented triggered activity in Tbx5^{fl/fl};R26^{CreERT2}. Representative APs recorded from (A) R26^{CreERT2}, (B) Tbx5^{fl/fl};R26^{CreERT2}, (C) Pln^{-/-};R26^{CreERT2}, (D) Tbx5^{fl/fl};Pln^{-/-};R26^{CreERT2}, (E) Tbx5^{fl/fl};Pln^{-/-};R26^{CreERT2} atrial cardiomyocytes as described previously in Figure 2. (F) TBX5-loss dependent AP prolongation and frequency of triggered activity was normalized by phospholamban knockout (myocytes/mice: n = 18/7 R26^{CreERT2}, n = 24/12 Tbx5^{fl/fl};R26^{CreERT2}, n = 12/5 Pln^{-/-};R26^{CreERT2}, n = 9/3 Tbx5^{fl/fl};Pln^{-/-};R26^{CreERT2}, and n = 22/3 Tbx5^{fl/fl};Pln^{-/-};R26^{CreERT2}), (*p<0.05, **p<0.01, ***p<0.001).

DOI: https://doi.org/10.7554/eLife.41814.025

The following source data is available for figure 6:

Source data 1. AP Parameters for Figure 6F.

DOI: https://doi.org/10.7554/eLife.41814.026
Figure 7. PLN deficiency protected against TBX5-loss associated AF. Intra-atrial pacing was used to induce AF. Representative intracardiac atrial electrogram recordings and corresponding surface ECG are shown from (A) R26CremERT2, (B) Tbx5fl/fl;R26CremERT2, (C) Pln+/−;R26CremERT2, (D) Tbx5fl/fl;Pln−/−;R26CremERT2, (E) Tbx5fl/fl;Pln−/−;R26CremERT2 atrial cardiomyocytes. A, atrial electrical signal; V, far field ventricular electrical signal. (F) AF was reproducibly induced by each condition as specified.
The mechanism causing cardiomyocyte depolarizations from depressed SERCA activity must be indirect, given that SERCA2 is localized to the intracellular SR membrane and therefore does not directly contribute to membrane potential itself. Instead, slowed SR calcium uptake from depressed SERCA function could be required to maintain systolic and diastolic calcium levels over the physiologic range of calcium in the cell. This suggests that 40 ms is insufficient to maintain calcium entry in TBX5 knockout cardiomyocytes. Together with our observation that nifedipine normalizes the APD, this supports that enhanced calcium entry impacts APD via secondary [Ca]2+ homeostasis. However, our observations that L-type calcium channel expression is TBX5-independent (Figures 1D and 2D) and that genetically targeting only the Ca2+ efflux pathways in our model is sufficient to restore normal electrical activity (Figures 5–7) suggest that the lCal change is not a primary TBX5-dependent effect. Furthermore, although lCal is increased, it quickly inactivates in TBX5 knockout cardiomyocytes (Figure 2F). Together with our observation that nifedipine normalizes the APD, this supports that enhanced calcium entry impacts APD via secondary [Ca]2+ dependent mechanisms.

**TBX5 loss results in reduced RyR2 expression**

In addition to identifying the role of altered NCX and SERCA function, we assessed the importance of TBX5-driven RyR2 expression. RyR2 is a known susceptibility locus for AF and RYR2 mutations are correlated with AF (Fatkin et al., 2017; Di Pino et al., 2014). We observed that RyR2 protein expression was significantly depressed following Tbx5 loss. Defective RyR2 function has also been associated with AF (Vest et al., 2005; King et al., 2013). Despite TBX5-dependent RyR2 expression, the ryanodine binding assay (Xu et al., 1998) suggested that RyR2 function is generally preserved over the physiologic range of calcium in Tbx5-mutant atria (Figure 3D). This suggests a compensatory mechanism must occur allowing for preserved RyR2 open probability in the setting of depressed
protein expression. For example, CaMKII is a potential regulator of RyR2 function which could increase the open probability and thereby increase steady leakage or favor spontaneous local Ca\(^{2+}\) release events from the SR (Vest et al., 2005; Neef et al., 2010; Fischer et al., 2015) in Tbx5-deficient mice. In line with such compensation, we could not detect any differences in the calcium rise kinetics during controlled square wave voltage clamp pulses (Figure 4—figure supplement 1). Nevertheless, RyR2 compensation in the setting of reduced expression could contribute to abnormal triggered activity in the setting of Tbx5 loss, and is an important topic for further investigation.

**Abnormalities of the TBX5/SERCA2/PLN regulatory axis drive AF formation**

We found that depressed SERCA function in TBX5 knockout was completely normalized with heterozygous or homozygous phospholamban knockout, which normalized AP duration, decreased frequency of afterdepolarizations, and reduced AF inducibility. This finding demonstrates the importance of SERCA2 to the pathophysiology of AF in the Tbx5-loss model. While phospholamban has been associated with AF by GWAS (Fatkin et al., 2017; Federico et al., 2017), its functional role is less clear. Although PLN is predominantly found in the ventricle (Bhupathy et al., 2007), we showed not only its expression is increased in the atria in the context of Tbx5 loss, but also PLN participates in rheostatic control of SERCA activity in the atria, which is sufficient to protect against AF inducibility (Figures 5–7). Our findings are further supported by patient studies. For example, in patients who experience post-operative AF, SERCA2 is significantly decreased in the atrial tissue (Zaman et al., 2016), but those with PLN mutations have decreased AF susceptibility in the context of arrhythmogenic right ventricular cardiomyopathy (Bourfiss et al., 2016). Thus, AF is a heterogeneous disease and there can be variability in how the calcium handling proteins are expressed (Dai et al., 2016) in different disease settings. The genetic background of an individual may be a critical determinant of how calcium handling moieties are disrupted to result in AF.

In summary, the most important features of the Tbx5-dependent SERCA2 and PLN regulatory axis are reduced SR uptake and load (Figure 8). In this setting, enhanced inward \(I_{\text{NCX}}\) and \(I_{\text{CaL}}\) contributes to AP prolongation, and, more importantly, to cardiomyocyte ectopy. Finally, we demonstrate PLN as a potential means to augment SERCA function, restoring normal atrial myocyte

**Figure 8.** Model of TBX5-dependent calcium regulation in atrial cardiomyocytes. (A) Excitation-contraction coupling of atrial cardiomyocytes is achieved through regulation of intracellular calcium handling. (B) Adult-specific Tbx5 knockout leads to decreased expression of SERCA2 and increased expression of PLN, leading to decreased SR Ca\(^{2+}\) load. In addition, removal of Tbx5 is associated with increased NCX1 expression and activity, thereby increasing Ca\(^{2+}\) extrusion, which is balanced by increased L-type calcium entry. (C) Combined Tbx5/Pln knockout relieves repression of SERCA2. This results in normalization of SERCA activity and rescue of cardiomyocyte ectopy, triggered activity, and AF observed with Tbx5 deficiency.

DOI: https://doi.org/10.7554/eLife.41814.028
electrical activity and normal sinus rhythm in Tbx5 knockout mice. Thus, the Tbx5 knockout model represents an excellent system to study pharmacologic rescue of SERCA activity, prevention of cardiomyocyte ectopy, and AF.

Broader implications for clinical treatment of AF

AF has become an increasingly common cause of morbidity and mortality, underlying over one-third of stroke cases and significantly increases the risk for heart failure (Nishida and Nattel, 2014). Consequently, AF poses a significant socioeconomic burden. AF does not always exist in isolation, but rather in conjunction with other predisposing factors such as obesity, thyroid hormone alterations, or heart failure. Interestingly, disruptions in calcium handling proteins such as the SERCA2-PLN regulatory axis are implicated as predisposing factors. In AF compounded by heart failure, decreased SERCA2 and phosphorylated PLN, and increased NCX1 expression were observed (Lugenbiel et al., 2015). Decrease in phosphorylated PLN coupled with an increase in total PLN has been found in animal models of obesity, potentially increasing risk of AF (Lima-Leopoldo et al., 2014; Lima-Leopoldo et al., 2008). These findings suggest a need to evaluate an individual’s genetic background as well as changes in calcium handling proteins when considering predisposing factors for AF.

Currently, there are few effective and targeted AF therapies, in part due to an incomplete understanding of the mechanisms underlying AF. Recent studies of specific genetic loci for AF susceptibility have opened new opportunities to identify specific mechanisms at play in subpopulations of AF patients. Understanding these specific mechanisms may facilitate more effective personalized therapies to target specific atrial Ca$^{2+}$ handling abnormalities. Our data is consistent with the knowledge that pharmacologic regulators of NCX1 or SERCA2 may normalize defects in cellular calcium handling in the atrium (Dobrev, 2010; Jost et al., 2013; Nagy et al., 2014; Ferrandi et al., 2013; Parikh et al., 2012). For example, a selective NCX1 inhibitor, ORM-10103, was shown to prevent cellular Ca$^{2+}$ handling abnormalities in ischemic ventricular cardiomyocytes, possibly by limiting calcium entry through outward I$_{\text{NCX}}$ (Jost et al., 2013; Kormos et al., 2014). The benefit of NCX inhibition might also be considered in human cases of AF with increased NCX activity. Further, resveratrol, which increases SERCA2 activity, has been shown to decrease AF, suggesting that targeting SERCA2 activity may be a viable therapeutic approach (Bai et al., 2016; Chong et al., 2015).

In addition to providing specific insight into treating TBX5-loss associated AF, our findings may be more broadly applied. These data suggest that pharmacological treatment of AF may be improved by assessing for a defect in the TBX5-SERCA2-PLN axis followed by specifically targeting the defect to restore normal cardiomyocyte electrical activity. We expect this work and continued efforts to uncover mechanisms responsible for AF in subpopulations of patients will play a key role in advancing personalized therapeutics for AF.

Materials and methods

| Key resources table |
|---------------------|-----------------------------|-------------------|----------------|------------------------|
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
| Genetic reagent (M. musculus) | Tbx5$^{fl/fl}$ (Tbx5$^{tm1Jse}$) | PMID: 11572777, 27582060 | MGI:2387850 | Dr. Jonathan G Seidman (Harvard) |
| Genetic reagent (M. musculus) | Pln$^{-/-}$ (Pln$^{tm1Egk}$) | PMID: 8062415 | MGI:2158357 | Dr. Evangelia Kranias (University of Cincinnati) |
| Genetic reagent (M. musculus) | Rosa26$^{CreERT2}$Gr(ROSA)26 Sop$^{tm1(cre/ERT2)Tyj}$ | PMID: 17251932, 27582060 | MGI:3790674 | Dr. Tyler Jacks (Massachusetts Institute of Technology) |
| Antibody | Mouse anti-RyR2 | ThermoFisher | Cat. #: MA3-925 | WB (1:2000) |
| Antibody | Mouse anti-SERCA2 | ThermoFisher | Cat. #: MA3-919 | WB (1:1000) |
| Antibody | Mouse anti-NCX | ThermoFisher | Cat. #: MA3-926 | WB (1:1000) |
| Antibody | Mouse anti-PLN | Badrilla | Cat. #: A010-14 | WB (1:5000) |
| Reagent type (species) or resource | Designation               | Source or reference | Identifiers | Additional information |
|----------------------------------|---------------------------|---------------------|-------------|------------------------|
| Antibody                         | Rabbit anti-pT17-PLN      | Badrilla            | Cat. #: A010-13 | WB (1:5000)            |
| Antibody                         | Rabbit anti-pS16-PLN      | Badrilla            | Cat. #: A010-12 | WB (1:5000)            |
| Antibody                         | Rabbit anti-Cav1.2        | Alomone             | Cat. #: ACC-003 | WB (1:200)             |
| Antibody                         | Mouse anti-GAPDH          | Millipore           | Cat. #: MAB374 | WB (1:10000)           |
| Antibody                         | Goat anti-mouse-HRP       | Thermofisher        | Cat. #: 31437 | WB (1:5000)            |
| Antibody                         | Goat anti-rabbit-HRP      | Thermofisher        | Cat. #: 31463 | WB (1:5000)            |
| Chemical compound, drug          | Fluo-4 AM                 | Thermofisher        | Cat. #: 14201 | 10 μM x 20 min         |
| Chemical compound, drug          | Nifedipine                | Sigma               | Cat. #: N7634 | 30 μM                  |
| Chemical compound, drug          | Collagenase Type 2        | Worthington Biochemical | Cat. #: LS004177 | 1 g/L                |
| Chemical compound, drug          | Tamoxifen                 | MP Biomedicals      | Cat#: 156738 | 2 mg/injection x three doses |
| Chemical compound, drug          | Laminin                   | Invitrogen          | Cat. #: 2039175 | 0.5 mg/ml             |
| Chemical compound, drug          | [3H]ryanodine             | PerkinElmer         | Cat. #: NET950250UC |                     |
| Chemical compound, drug          | TRIzol                    | Invitrogen          | Cat. #: 15596026 |                     |
| Chemical compound, drug          | Ryanodine                 | MP Biomedicals      | SKU #.0215377001 |                     |
| Chemical compound, drug          | Caffeine                  | Sigma               | Cat. #: C0750 | 10 mM                  |
| Software, algorithm              | Clampex/Clampfit          | Molecular Devices   | Version 10.3.2.1 |                     |
| Software, algorithm              | LabChart for electrophysiology studies | ADInstruments | Version 5 and 8 |                     |
| Software, algorithm              | Buffering analyses using MaxChelator | Stanford | WEBMAXCLITE v1.15 | Chris Patton, Stanford University |
| Software, algorithm              | Western Blot quantification ImageJ | NIH | Version 1.48 |                     |
| Software, algorithm              | Hierarchical Statistical technique using R | R Core Team | Script from PMID: 29016722 | Ken Macleod, Imperial College London |
| Commercial Assay or Kit          | qScript cDNA synthesis kit | Quanta             |             |                       |
| Commercial Assay or Kit          | Power SYBR Green PCR Master Mx | Applied Biosystems |             |                       |

**Generation of mice**

The Tbx5\(^{fl/fl}\), Pln\(^{-/-}\) and Rosa26\(^{CreERT2}\) lines have all been previously described and were kept in a mixed genetic background (Luo et al., 1994; Bruneau et al., 2001; Ventura et al., 2007). Double knockout mice were generated by crossing Tbx5\(^{fl/fl}\);R26\(^{CreERT2}\) mice with germline Pln\(^{-/-}\) mice. After two generations, we obtained Tbx5\(^{fl/fl}\);R26\(^{CreERT2}\) mice with either loss of one (Pln\(^{+/+}\)) or both (Pln\(^{-/-}\)) copies of Pln. All experiments were done using age- and genetic strain-matched littermate controls. Tamoxifen was administered for three consecutive days at a dose of 0.167 mg/kg body weight by intraperitoneal injection at 6–10 weeks of age, as previously described (Nadadur et al., 2016). All experiments were performed in accordance to The University of Chicago Institutional Animal Care and Use Committee (IACUC) approved protocol.
ECG recordings

8-to 10-week-old mice were anesthetized using isoflurane, and telemetry transmitters (ETA-F10, Data Science International) were implanted in the back with leads tunneled to the right upper and left lower thorax, as previously described (Wheeler MT et al., JCI 2004). Baseline recordings were obtained for 24 hr after a post-implant recovery period of one day. ECG data was analyzed using LabChart 8 (AD Instruments).

Intracardiac electrophysiology studies

Detailed protocols for intracardiac electrograms have been previously described (Nadadur et al., 2016). Briefly, 8- to 10-week-old mice were anesthetized with isoflurane and a vertical skin cut-down at the right jugular vein was performed. A 1.1 F octapolar catheter (EPR-800, Millar Instruments) was advanced in the right jugular vein to perform electrical stimulation. The catheter was connected to ADI BioAmp and PowerLab apparatus and signals were recorded using LabChart Software (ADInstruments). Atrial induction pacing was performed using burst pacing and the presence of at least three cycles of atrial tachycardia or fibrillation at least twice was considered positive.

\[\text{Ca}^{2+}\] transient measurement

Langendorff perfusion with 2 mg/mL of Collagenase Type 2 (Worthington Biochemical) at 5 ml/min was used to isolate atrial cardiomyocytes. Cardiomyocytes were then plated on laminin coated glass bottom dishes for 30 min prior to incubation with 10 μM Fluo-4/AM (Molecular Probes/Invitrogen) in normal Tyrode’s solution containing (in mM): 140 NaCl, 4 KCl, 10 glucose, 10 HEPES, and 1 MgCl2, 1 CaCl2 pH 7.4 using NaOH for 20 min at room temperature. Cells were perfused with prewarmed Tyrode for 10 min prior to imaging. Imaging was performed on an Olympus microscope with a 20x objective lens, a LAMBDA DG-4 power source with 488 nm excitation and 515 nm emission filters and a PMT (photomultiplier tube) to record whole cell signal. Electrical field stimulation (Grass stimulator; Astro-Med) was performed at 1 Hz. SERCA and NCX measurements were performed by flowing sodium free Tyrode with 10 mM caffeine followed by sodium free Tyrode alone or Tyrode with caffeine respectively. Cells were returned to normal Tyrode in both cases at the end of the recording. [Ca^{2+}] transient transients are presented as total fluorescence intensity normalized to resting fluorescence (F/F0) obtained from steady-state resting conditions before field stimulation. [Ca^{2+}] transient transients and sparks were acquired in line-scan mode (3 ms per scan; pixel size 0.12 μm) using a Zeiss confocal microscope.

Whole-cell electrophysiological recordings

APs and voltage clamp recordings were recorded using standard ruptured patch protocol (Nadadur et al., 2016). We used current clamp mode with 0.5 nA × 2 ms current clamp pulses to measure APs. Voltage clamp mode was used to measure capacitance transients and to study [Ca^{2+}] transient transients with fixed duration depolarizations. Cardiomyocytes are kept at 37°C and perfused with Tyrode solution (140 NaCl, 4 KCl, 1 MgCl2, 1 CaCl2, 10 HEPES, and 10 glucose, and pH 7.4 with NaOH). Internal pipette solution composition was (in mM): 20 KCl, 100 K-glutamate, 10 HEPES 5 MgCl2, 2 Mg-ATP, 0.3 Na-GTP. Patch pipettes (World Precision Instruments) were pulled to have a mean resistance of 3.5–5 MΩ. An Ag–AgCl pellet and 3M KCl agar bridge was used to ground the bath. Liquid junction potentials, were always corrected after cell rupture.

External solution for I_{CaL} contained (in mM): 120 Tetraethylammonium-chloride, 10 CsCl, 10 Glucose, 10 HEPES, 1.5 MgCl2, 1 CaCl2, pH 7.4 with CsOH. Internal pipette solution contained (in mM): 100 Cs-methanesulfonate, 30 CsCl, 10 HEPES 5 EGTA, 2 MgCl2, 5 Mg-ATP, pH 7.2 with CsOH. I_{CaL} was recorded during 200 ms voltage clamp pulses from a holding potential of −40 mV to test potentials ranging from −40 to 60 mV, with pulses applied every 2 s in 5 mV increments. Peak current amplitudes were normalized to the cell capacitance (Cm) and presented as current density (A/F).

Steady-state inactivation of I_{CaL} was investigated using two-pulse protocol. Holding potential was −80 mV. The first pulse depolarized membrane from −60 to 20 mV with 10 mV increments during 500 ms, the second pulse depolarized the membrane to 10 mV for 50 ms. The inactivation curves were fit to a Boltzmann distribution.

Acquisition was performed using an Axopatch-200B amplifier connected to a Digidata1550A acquisition system (Axon Instruments, Foster City, CA, USA). In recording filtering at 2 kHz was
performed using the amplifier Bessel and sampled at 10 kHz. Analysis was performed using 
pCLAMP10 (Axon Instruments) and a home written analysis code.

**Western blots**

Atrial tissue was collected and homogenized as described previously (Alvarado et al., 2017), in a 
buffer containing 0.9% NaCl, 10 mM Tris-HCl pH 6.8, 20 mM NaF and protease inhibitors. Equal 
amounts of protein, as determined by Bradford assay, were loaded. 50 μg of tissue homogenate, in 
Laemmli buffer, was separated by SDS-PAGE in 4–20% TGX or AnyKD precast gels (Bio-Rad). Pro-
teins were transferred to PVDF membrane using the iblot2 transfer system (ThermoFisher) or wet 
transfer. Primary antibodies were as follows: anti-RyR2 (1:2000; MA3-925, ThermoFisher), SERCA2 
(1:1000; MA3-919, ThermoFisher), NCX (1:1000; MA3-926, ThermoFisher), PLN (1:5000; A010-14, 
Badrilla), pT17-PLN (1:5000; A010-13, Badrilla), pS16-PLN (1:5000; A010-12, Badrilla), Cav1.2 (1:200; 
ACC-003, Alomone), GAPDH (1:10000; MAB374, Millipore). Secondary antibodies were: goat anti-
mouse-HRP (1:5000; 31437, ThermoFisher) or goat anti-rabbit-HRP (1:5000; 31463, ThermoFisher). Sec-
ondary antibody concentrations were 5x higher when using the ibind Flex system. SuperSignal 
ECL reagent (ThermoFisher) was used to develop membranes followed by imaging with a ChemiDoc 
MP apparatus (Bio-Rad). Band intensities were quantified with the ImageLab software (Bio-Rad) or 
using ImageJ (NIH).

[^3]H]Ryanodine binding assay

Binding assays were carried out following a protocol previously described (Federico et al., 2017). 
Binding mixtures contained 100 μg of protein from homogenates prepared from pooled atria (5–7 
mice), 0.2 M KCl, 20 mM Heps (pH 7.4), 6.5 nM [^3]H]ryanodine (PerkinElmer), 1 mM EGTA and 
enough CaCl₂ to set free [Ca²⁺] between 10 nM (pCa²⁺ 8) and 100 μM (pCa²⁺ 4). The ratio between 
Ca²⁺ and EGTA was determined using MaxChelator (WEBMaxCLITE v1.15 http://maxchelator.stan-
ford.edu/webmaxclite115.htm). Following a 2 hr incubation at 36˚C, reactions were fil-
tered through Whatman GF/B Filters using a Brandel M24-R Harvester. [^3]H]ryanodine binding was 
determined using a Beckman LS6500 scintillation counter and BioSafe II scintillation cocktail (RPI 
Corp). Non-specific binding was quantified in the presence of 2 μM unlabeled ryanodine (MP Bio-
medicals) and subtracted.

**Quantitative real time PCR**

Left atrial tissue of Tbx5^CreERT2^-fl/fl;R26^CreERT2^- and R26^CreERT2^- mice was removed two weeks after receiving 
tamoxifen and RNA was isolated using a Trizol (Invitrogen) based method. Reverse transcription 
reaction was carried out using the qScript CDNA synthesis kit (Quanta) according to the manufac-
turer’s protocol. Quantitative RT-PCR was performed using the Power SYBR Green PCR Master Mix 
(Applied Biosystems) and run on an Applied Biosystems AB7500 machine. Relative fold changes 
were calculated using the comparative threshold cycle method (2^(-ΔΔCt)), using glyceraldehyde-3-phos-
phate dehydrogenase (Gapdh) gene expression level as internal control.

**PCR primers**

| Gene | F primer | R primer |
|------|----------|----------|
| Tbx5 | GGCAAGGAGAATCAAGGT | CTAGGAAACATTCCTCCTCCCTGC |
| RyR2 | CAAATCCTCTGCGTCCCAAG | CGAGGAGTGAAGTCCAGTTCC |
| Atp2a2 | CTGGTGATATAGTGGAAATTGCTG | GGTCAGGGACAGGGTCAGTA |
| Pln | TTAGCCAGGACCGCACAAAAG | CACTGTGACGATACCGAAG |
| Sln | CTCAGGCTTGTGATAGTCC | GGTGTGATCCAGGTCGAG |
| Cacna1c | CTACAGAACCACCATGGACCAT | CAGCCACGTGTCAGTTG |
| Ncx1 | TTTCTATACCTCTCGTCATCG | TTGAGGACACCTGGAGAGT |
| Calm1 | TGGGAATGGTGGATTACCTGTC | CGCCATCATATCTGCTCTCT |
| Calm2 | ACGGGGATGGGACAATACAA | TGTCGACTAATATAGCCATTC |
| Calm3 | GATGGCACCATTACCAACCGAAG | CGCTGCTGTATCTCCTCATCTT |

Dai et al. eLife 2019;8:e41814. DOI: https://doi.org/10.7554/eLife.41814
**Statistical analysis**

Values are represented as mean ± standard error of the mean (±SEM). Statistical significance for quantitative metrics of APs, SERCA, NCX, SR load, I_{CaL}, spark frequency, and [Ca^{2+}]_i transients were determined using hierarchical statistical methods (Sikkel et al., 2017). Statistical significance for mRNA, and protein expression studies was determined using Student’s t-test. Statistical significance of the nifedipine effect on AP duration was determined using two-tailed paired t-test. A two-tailed Fisher’s exact test was used for statistical significance of count-based analysis of AF inducibility and EAD and DAD count. Statistical significance is designated as *p<0.05, **p<0.01, and ***p<0.001.

**Acknowledgements**

We thank Evangalia Kranias for providing the phospholamban knockout mice (NIH HL26057). The project described was supported by R01 HL126509 and HL114010, AHA Collaborative Sciences Award, R33 HL123857, and T32HL007381.

**Additional information**

| Funding | Grant reference number | Author |
|---------|-------------------------|--------|
| National Institutes of Health | HL126509 | Ivan P Moskowitz |
| American Heart Association | Collaborative Sciences Award | Ivan P Moskowitz |
| National Institutes of Health | T32HL007381 | Wenli Dai |
| National Institutes of Health | HL114010 | Ivan P Moskowitz |
| National Institutes of Health | R33 HL123857 | Ivan P Moskowitz |
| National Institutes of Health | T32GM007281 | Wenli Dai |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

**Author contributions**

Wenli Dai, Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing; Brigitte Laforest, Conceptualization, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing; Leonid Tyan, Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Writing—review and editing; Kaitlyn M Shen, Conceptualization, Data curation, Investigation, Visualization, Writing—review and editing; Rangarajan D Nadadur, Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Visualization, Methodology, Writing—review and editing; Francisco J Alvarado, Conceptualization, Software, Formal analysis, Investigation, Visualization, Writing—review and editing; Stefan R Mazurek, Conceptualization, Investigation, Methodology, Writing—review and editing; Sonja Lazarovic, Investigation, Methodology, Writing—review and editing; Margaret Gadek, Investigation, Writing—review and editing; Yitang Wang, Conceptualization, Data curation, Formal analysis, Writing—review and editing; Ye Li, Conceptualization, Data curation, Software, Formal analysis, Supervision, Investigation, Visualization, Methodology, Writing—review and editing; Hector H Valdivia, Conceptualization, Supervision, Investigation, Methodology, Writing—review and editing; Le Shen, Conceptualization, Formal analysis, Supervision, Investigation, Methodology, Project administration, Writing—review and editing; Michael T Broman, Conceptualization, Formal analysis, Supervision, Project administration, Writing—review and editing; Ivan P Moskowitz, Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration; Christopher R Weber, Conceptualization, Resources, Software, Supervision, Funding acquisition, Validation, Investigation,
Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing

Author ORCIDs
Wenli Dai http://orcid.org/0000-0003-4328-9740
Brigitte Laforest http://orcid.org/0000-0001-6919-8922
Leonid Tyan http://orcid.org/0000-0001-9734-7286
Francisco J Alvarado http://orcid.org/0000-0003-0552-9029
Ye Li http://orcid.org/0000-0002-2969-2894
Le Shen http://orcid.org/0000-0002-4367-5476
Ivan P Moskowitz https://orcid.org/0000-0003-0014-4963
Christopher R Weber http://orcid.org/0000-0002-2117-3184

Ethics
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#71737) of the University of Chicago. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Chicago. All surgery was performed under isoflurane anesthesia, and every effort was made to minimize suffering.

Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.41814.031
Author response https://doi.org/10.7554/eLife.41814.032

Additional files
Supplementary files
• Transparent reporting form

DOI: https://doi.org/10.7554/eLife.41814.030

Data availability
All data generated or analysed during this study are included in the manuscript and supporting files.

References
Alvarado FJ, Chen X, Valdivia HH. 2017. Ablation of the cardiac ryanodine receptor phospho-site Ser2808 does not alter the adrenergic response or the progression to heart failure in mice. Elimination of the genetic background as critical variable. Journal of Molecular and Cellular Cardiology 103:40–47. DOI: https://doi.org/10.1016/j.yjmcc.2017.01.001, PMID: 28065668

Andrade J, Khairy P, Dobrev D, Nattel S. 2014. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circulation Research 114:1453–1468. DOI: https://doi.org/10.1161/CIRCRESAHA.114.303211, PMID: 24763464

Bai T, Hu X, Zheng Y, Wang S, Kong J, Cai L. 2016. Resveratrol protects against lipopolysaccharide-induced cardiac dysfunction by enhancing SERCA2a activity through promoting the phospholamban oligomerization. American Journal of Physiology-Heart and Circulatory Physiology 311:H1051–H1062. DOI: https://doi.org/10.1152/ajpheart.00296.2016, PMID: 27591219

Bers DM, Grandi E. 2011. Human atrial fibrillation: insights from computational electrophysiological models. Trends in Cardiovascular Medicine 21:145–150. DOI: https://doi.org/10.1016/j.tcm.2012.04.004, PMID: 22732550

Bhupathy P, Babu GJ, Periasamy M. 2007. Sarcolipin and phospholamban as regulators of cardiac sarcoplasmic reticulum Ca\(^{2+}\) ATPase. Journal of Molecular and Cellular Cardiology 42:903–911. DOI: https://doi.org/10.1016/j.yjmcc.2007.03.738, PMID: 17442337

Blaustein MP, Lederer WJ. 1999. Sodium/calcium exchange: its physiological implications. Physiological Reviews 79:763–854. DOI: https://doi.org/10.1152/physrev.1999.79.3.763, PMID: 10390518

Bourfiss M, Te Riele AS, Mast TP, Cramer MJ, VAN DER Heijden JF, VAN Veen TA, Loh P, Dooijes D, Hauer RN, Velthuis BK. 2016. Influence of Genotype on Structural Atrial Abnormalities and Atrial Fibrillation or Flutter in...
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. *Journal of Cardiovascular Electrophysiology* 27:1420–1428. DOI: https://doi.org/10.1111/jce.13094, PMID: 27572111

Brundel BJ, van Gelder IC, Henning RH, Tuinenburg AE, Deelman LE, Tieleman RG, Grandjean JG, van Gilst WH, Crijs HJ. 1999. Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. *Cardiovascular Research* 42:443–454. DOI: https://doi.org/10.1016/S0009-9263(99)00045-0, PMID: 10533580

Bruneau BG, Nemergut G, Schmitt JP, Charron F, Robitaille L, Caron S, Conner DA, Gessler M, Nemergut M, Seidman CE, Seidman JG. 2001. A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. *Cell* 106:709–721. DOI: https://doi.org/10.1016/S0092-8674(01)00493-7, PMID: 11572777

Chong E, Chang SL, Hsiao YW, Singhal R, Liu SH, Leha T, Lin WY, Hsu CP, Chen YC, Chen YJ, Wu TJ, Higa S, Chen SA. 2015. Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K/AKT/eNOS signaling pathway activation. *Heart Rhythm* 12:1046–1056. DOI: https://doi.org/10.1016/j.hrthm.2015.01.044, PMID: 25460364

Christophersen IE, Ravn LS, Budtz-Joergensen E, Skytte A, Haunssoe S, Svendsen JH, Christensen K. 2009. Familial aggregation of atrial fibrillation: a study in Danish twins. *Circulation. Arrhythmia and electrophysiology* 2:378–383. DOI: https://doi.org/10.1161/CIRCEP.108.786665, PMID: 19808493

Dai J, Zhang H, Chen Y, Chang Y, Yuan Q, Ji G, Zhai K. 2016. Characterization of Ca\(^{2+}\) handling proteins and contractile proteins in patients with lone atrial fibrillation. *International Journal of Cardiology* 202:749–751. DOI: https://doi.org/10.1016/j.ijcard.2015.10.010, PMID: 26474465

Di Pino A, Caruso E, Costanzo L, Guccione P. 2014. A novel RyR2 mutation in a 2-year-old baby presenting with atrial fibrillation, atrial flutter, and atrial ectopic tachycardia. *Heart Rhythm* 11:1480–1483. DOI: https://doi.org/10.1016/j.hrthm.2014.04.037, PMID: 24793461

Dobrev D. 2010. Atrial Ca\(^{2+}\) signaling in atrial fibrillation as an antiarrhythmic drug target. *Naunyn-Schmiedeberg’s Archives of Pharmacology* 381:195–206. DOI: https://doi.org/10.1007/s00210-009-0457-1, PMID: 19784635

El-Armouche A, Boknik P, Eschenhagen T, Carrier L, Knaut M, Ravens U, Dobrev D. 2006. Molecular determinants of altered Ca\(^{2+}\) handling in human chronic atrial fibrillation. *Circulation* 114:670–680. DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.636845, PMID: 16894034

Fatkin D, Santiago CF, Huttnig IG, Lubitz SA, Ellinor PT. 2017. Genetics of Atrial Fibrillation: State of the Art in 2017. *Heart, Lung and Circulation* 26:894–901. DOI: https://doi.org/10.1016/j.hlcc.2017.04.008, PMID: 28601532

Federico M, Portiansky EL, Sommese L, Alvarado FJ, Blanco PG, Lanuzzi CN, Dedman J, Kaetzel M, Wehrens XHT, Mattiazzi A, Palomeque J. 2017. Calcium-calmodulin-dependent protein kinase mediates the intracellular signalling pathways of cardiac apoptosis in mice with impaired glucose tolerance. *The Journal of Physiology* 595:4089–4108. DOI: https://doi.org/10.1113/jp273714, PMID: 28105734

Ferrandi M, Barassi P, Radini-Buonisegni F, Bartolommei M, Molinari I, Tripodi MG, Reina C, Moncelli MR, Bianchi G, Ferrari P. 2013. Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition. *British Journal of Pharmacology* 169:1849–1861. DOI: https://doi.org/10.1111/bph.12278, PMID: 23763364

Fischer TH, Herting J, Mason FE, Hartmann N, Watanabe S, Nikolaev VO, Sprenger JU, Fan P, Yao L, Popov AF, Danner BC, Schöndube F, Belardini L, Hasenfuss G, Maier LS, Sossalla S. 2015. Late INa increases diastolic SR Ca\(^{2+}\)-leak in atrial myocytes by activating PKA and CaMKII. *Cardiovascular Research* 107:184–196. DOI: https://doi.org/10.1093/eurheartj/ehv070, PMID: 25990311

Grandi E, Pandit SV, Voigt N, Workman AJ, Dobrev D, Jalife J, Bers DM. 2011. Human atrial action potential and Ca\(^{2+}\) model: sinus rhythm and chronic atrial fibrillation. *Circulation research* 109:1055–1066. DOI: https://doi.org/10.1161/CIRCRESAHA.111.253955, PMID: 21921263

Greiser M, Lederer WJ, Schotten U. 2011. Alterations of atrial Ca\(^{2+}\) handling as cause and consequence of atrial fibrillation. *Cardiovascular Research* 89:722–733. DOI: https://doi.org/10.1093/cvr/cvq389, PMID: 21159669

Heijman J, Voigt N, Nettel S, Dobrev D. 2014. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. *Circulation Research* 114:1483–1499. DOI: https://doi.org/10.1161/CIRCRESAHA.114.302226, PMID: 24763466

Hove-Madsen L, Llach A, Bayes-Genís A, Roura S, Rodriguez Font E, Arís A, Cinca J. 2004. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. *Circulation* 110:1358–1363. DOI: https://doi.org/10.1161/01.CIR.0000141296.59876.87, PMID: 15313939

Jost N, Nagy N, Corici C, Kohajda Z, Horváth A, Acsai K, Biliczki P, Levijoki J, Pollesello P, Koskelainen T, Otosmaa L, Tóth A, Papp JG, Varró A, Virág L. 2013. ORM-10103, a novel specific inhibitor of the Na\(^+/Ca\(^{2+}\) exchanger, decreases early and delayed afterdepolarizations in the canine heart. *British Journal of Pharmacology* 170:768–778. DOI: https://doi.org/10.1111/bph.12228, PMID: 23647096

King JH, Zhang Y, Lei M, Grace AA, Huang CL, Fraser JA. 2013. Atrial arrhythmia, triggering events and conduction abnormalities in isolated murine RyR2-P2328S hearts. *Acta Physiologica* 207:308–323. DOI: https://doi.org/10.1111/apha.12006, PMID: 22958452

Kosmos A, Nagy N, Acsai K, Váčzi K, Agoston S, Pollesello P, Levijoki J, Szentandrassy N, Papp JG, Varró A, Tóth A. 2014. Efficacy of selective NCX inhibition by ORM-10103 during simulated ischemia/reperfusion. *European Journal of Pharmacology* 740:539–551. DOI: https://doi.org/10.1016/j.ejphar.2014.06.033, PMID: 24975099
Lenaerts I, Bito V, Heinzl FR, Driesen RB, Holemans P, D’hooge J, Heidbüchel H, Sipido KR, Willems R. 2009. Ultrastructural and functional remodeling of the coupling between Ca\textsuperscript{2+} influx and sarcoplasmic reticulum Ca\textsuperscript{2+} release in right atrial myocytes from experimental persistent atrial fibrillation. *Circulation Research* **105**:876–885. DOI: https://doi.org/10.1161/CIRCRESAHA.109.206276, PMID: 19762679

Li L, Louch WE, Niederer SA, Andersson KB, Christensen G, Sejersted OM, Smith NP. 2011. Calcium dynamics in the ventricular myocytes of SERCA2A knockout mice: A modeling study. *Biophysical Journal* **100**:322–331. DOI: https://doi.org/10.1016/j.bpj.2010.11.046, PMID: 21244828

Liang X, Xie H, Zhuh PH, Hu J, Zhao Q, Wang CS, Yang C. 2008. Ryanodine receptor-mediated Ca\textsuperscript{2+} events in atrial myocytes of patients with atrial fibrillation. *Cardiology* **111**:102–110. DOI: https://doi.org/10.1159/000119697, PMID: 18376121

Lima-Leopoldo AP, Sugizaki MM, Leopoldo AS, Carvalho RF, Nogueira CR, Nascimento AF, Martinez PF, Luvisotto RA, Padovani CR, Cicogna AC. 2008. Obesity induces upregulation of genes involved in myocardial Ca\textsuperscript{2+} handling. *Brazilian Journal of Medical and Biological Research* **41**:615–620. DOI: https://doi.org/10.1590/S0100-879X2008000700011, PMID: 18719744

Lima-Leopoldo AP, Leopoldo AS, da Silva DC, do Nascimento AF, de Campos DH, Luvisotto RA, de Deus AF, Freire PP, Medeiros A, Okashi K, Cicogna AC. 2014. Long-term obesity promotes alterations in diastolic function induced by reduction of phospholamban phosphorylation at serine-16 without affecting calcium handling. *Journal of Applied Physiology* **117**:669–678. DOI: https://doi.org/10.1152/japplphysiol.00088.2014, PMID: 24970835

Lugeniël P, Wenz F, Govorov K, Schweizer PA, Katus HA, Thomas D. 2015. Atrial fibrillation complicated by heart failure induces distinct remodeling of cardiac cycling proteins. *PLoS One* **10**:e0116395. DOI: https://doi.org/10.1371/journal.pone.0116395, PMID: 25775120

Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ, Doetschman T, Kranias EG. 1994. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. *Circulation Research* **75**:401–409. DOI: https://doi.org/10.1161/01.RES.75.3.401, PMID: 8062415

Macquaide N, Tuan HT, Hotta J, Sempels W, Lenaerts I, Holemans P, Hofkens J, Jafari MS, Willems R, Sipido KR. 2015. Ryanodine receptor cluster fragmentation and redistribution in persistent atrial fibrillation enhance calcium release. *Cardiovascular Research* **108**:387–398. DOI: https://doi.org/10.1093/cvr/cv231, PMID: 26490742

McDermott DA, Hatcher CJ, Basson CT. 2008. Atrial Fibrillation and Other Clinical Manifestations of Altered TBX5 Dosage in Typical Holt-Oram Syndrome. *Circulation Research* **103**:e96. DOI: https://doi.org/10.1161/CIRCRESAHA.108.181834, PMID: 18818049

Nadadur RD, Bromran MT, Boukens B, Mazurek SR, Yang X, van den Boogaard M, Beken J, Gadek M, Ward T, Zhang M, Qiao Y, Martin JF, Seidman CE, Seidman J, Christoffels V, Efimov IR, McNally EM, Weber CR, Moskowitz IP. 2016. Phlx2 modulates a Tbx5-dependent gene regulatory network to maintain atrial rhythm. *Science Translational Medicine* **8**:ra115. DOI: https://doi.org/10.1126/scitransmed.aaf4891, PMID: 27582060

Nagy N, Kormos A, Kohajda Z, Szebeni A, Szepesi J, Pollesello P, Levisi J, Nánásı P, Papp JG, Varró A, Tóth A. 2014. Selective Na\textsuperscript{+}/Ca\textsuperscript{2+} exchanger inhibition prevents Ca\textsuperscript{2+} overload-induced triggered arrhythmias. *British journal of pharmacology* **171**:5665–5681. DOI: https://doi.org/10.1111/bjp.12867, PMID: 25073832

Neef S, Dybkova N, Sossalla S, Ort KR, Fluschnik N, Neumann K, Seipel R, Schöndube FA, Hasenfuss G, Maier LS. 2010. CalMklII-dependent diastolic SR Ca\textsuperscript{2+} leak and elevated diastolic Ca\textsuperscript{2+} levels in right atrial myocardium of patients with atrial fibrillation. *Circulation Research* **106**:1134–1144. DOI: https://doi.org/10.1161/CIRCRESAHA.109.203836, PMID: 20056922

Nishida K, Nattel S. 2014. Atrial fibrillation complicandum: historical context and detailed translational perspective on an important clinical problem. *Circulation Research* **114**:1447–1452. DOI: https://doi.org/10.1161/CIRCRESAHA.114.303466, PMID: 24763463

Parikh A, Mantravadi R, Kozhevnikov D, Roche MA, Ye Y, Owen LJ, Puglisi JL, Abramson JJ, Salama G. 2012. Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2. *Heart Rhythm* **9**:953–960. DOI: https://doi.org/10.1016/j.hrthm.2012.01.010, PMID: 22245792

Shanmugam M, Molina CE, Gao S, Severac-Bastide R, Fischmeister R, Babu GJ. 2011. Decreased sarcolipin protein expression and enhanced sarco(endo)plasmic reticulum calcium Ca\textsuperscript{2+} uptake in human atrial fibrillation. *Biochemical and Biophysical Research Communications* **410**:97–101. DOI: https://doi.org/10.1016/j.bbrc.2011.05.113, PMID: 21640081

Silke MB, Francis DP, Howard J, Gordon F, Rowlands C, Peters NS, Lyon AR, Harding SE, MacLeod KT. 2017. Hierarchical statistical techniques are necessary to draw reliable conclusions from analysis of isolated cardiomyocyte studies. *Cardiovascular Research* **113**:1743–1752. DOI: https://doi.org/10.1093/cvr/cvx151, PMID: 29016722

Sinner MF, Tucker NR, Lunetta KL, Ozaki K, Smith JG, Trompet S, Bis JC, Lin H, Chung MK, Nielsen JB, Lubitz SA, Krijthe BP, Magnani JW, Ye J, Gollob MH, Tsunoda T, Müller-Nurasyid M, Lichtner P, Peters A, Dolmatova E, et al. 2014. Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation. *Circulation* **130**:1225–1235. DOI: https://doi.org/10.1161/CIRCULATIONAHA.114.009892, PMID: 25124494
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. 2007. Restoration of p53 function leads to tumour regression in vivo. *Nature* **445**:661–665. DOI: https://doi.org/10.1038/nature05541, PMID: 17251932

Vest JA, Wehrens XH, Reiken SR, Lennart SE, Dobrev D, Chandra P, Danilo P, Ravens U, Rosen MR, Marks AR. 2005. Defective cardiac ryanodine receptor regulation during atrial fibrillation. *Circulation* **111**:2025–2032. DOI: https://doi.org/10.1161/01.CIR.0000162461.67140.AC, PMID: 15851612

Voigt N, Li N, Wang Q, Wang W, Trafford AW, Abu-Taha I, Sun Q, Wieland T, Ravens U, Nattel S, Wehrens XH, Dobrev D. 2012. Enhanced sarcoplasmic reticulum Ca\(^{2+}\) leak and increased Na\(^+-\)Ca\(^{2+}\) exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. *Circulation* **125**:2059–2070. DOI: https://doi.org/10.1161/CIRCULATIONAHA.111.067306, PMID: 22456474

Voigt N, Heijman J, Wang Q, Chiang DY, Li N, Karck M, Wehrens XHT, Nattel S, Dobrev D. 2014. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. *Circulation* **129**:145–156. DOI: https://doi.org/10.1161/CIRCULATIONAHA.113.006641, PMID: 24249718

Weng LC, Preis SR, Hulme OL, Larson MG, Choi SH, Wang B, Trinquart L, McManus DD, Staerk L, Lin H, Lunetta KL, Ellinor PT, Benjamin EJ, Lubitz SA. 2018. Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial Fibrillation. *Circulation* **137**:1027–1038. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.031431, PMID: 29129827

Xu L, Eu JP, Meissner G, Stamler JS. 1998. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. *Science* **279**:234–237. DOI: https://doi.org/10.1126/science.279.5348.234, PMID: 9422697

Yang XH, Nadadur RD, Hilvering CR, Bianchi V, Werner M, Mazurek SR, Gadek M, Shen KM, Goldman JA, Tyan L, Bekenyi J, Hall JM, Lee N, Perez-Cervantes C, Burnicka-Turek O, Poss KD, Weber CR, de Laat W, Ruthenburg AJ, Moskovitz IP. 2017. Transcription-factor-dependent enhancer transcription defines a gene regulatory network for cardiac rhythm. *elife* **6**:e31683. DOI: https://doi.org/10.7554/elife.31683, PMID: 29280435

Zaman JA, Harling L, Ashrafian H, Darzi A, Gooderham N, Athanasiou T, Peters NS. 2016. Post-operative atrial fibrillation is associated with a pre-existing structural and electrical substrate in human right atrial myocardium. *International Journal of Cardiology* **220**:580–588. DOI: https://doi.org/10.1016/j.ijcard.2016.06.249, PMID: 27390994